We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
Read MoreHide Full Article
We expect Zoetis Inc. (ZTS - Free Report) to surpass expectations when it reports first-quarter 2021 results on May 6 before market opens.
The company’s earnings surprise history has been excellent so far, having surpassed expectation in each of the trailing four quarters, the average beat being 18.05%. In the last-reported quarter, Zoetis delivered an earnings surprise of 5.81%.
Shares of Zoetis have increased 4.5% in the year so far against the industry’s decrease of 8.4%.
Let's see how things are shaping up for this announcement.
Factors to Consider
Zoetis derives a majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
Solid sales from the dermatology portfolio strengthened the United States segment in the last-reported quarter, a trend that most likely continued in the first quarter as well. The company’s companion animal business has also been performing well, primarily owing to higher sales of the SimparicaTrio – the recently launched triple combination parasiticide for dogs.
In the last-reported quarter, sales of cattle products declined year over year – a trend that most likely continued in the first quarter as well. Sales of both swine and poultry products also declined in the last-reported quarter due to unfavorable market conditions related to the COVID-19 pandemic, a trend that most likely continued in the first quarter as well.
For the International segment, sales of companion animal products increased in the last-reported quarter. Sales also benefited as clinics expanded their operations following less COVID-19-related restrictions. The trend is expected to have continued in the first quarter as well. Growth in the company’s fish portfolio also went up due to increased market share for salmon vaccines and the acquisition of Fish Vet Group, a trend that most likely continued in the first quarter as well.
In February 2021, the European Commission granted marketing authorization to Solensia (frunevetmab) – a new feline osteoarthritis ("OA") treatment to alleviate pain. Solensia is the first injectable mAb licensed for the alleviation of pain associated with OA in cats. We expect more updates on the same at the upcoming earnings call.
Why a Likely Positive Surprise?
Our proven model predicts an earnings beat for Zoetis this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Zoetis has an Earnings ESP of +2.77% as the Zacks Consensus Estimate stands at $1.04 per share while the Most Accurate Estimate is pegged at $1.07 per share.
Here are some other drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Axsome Therapeutics, Inc. (AXSM - Free Report) with an Earnings ESP of +23.83% and a Zacks Rank #3. The company is scheduled to report earnings on May 10.
Aerie Pharmaceuticals, Inc. with an Earnings ESP of +6.25% and a Zacks Rank #2. The company is scheduled to report earnings on May 5.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Shutterstock
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
We expect Zoetis Inc. (ZTS - Free Report) to surpass expectations when it reports first-quarter 2021 results on May 6 before market opens.
The company’s earnings surprise history has been excellent so far, having surpassed expectation in each of the trailing four quarters, the average beat being 18.05%. In the last-reported quarter, Zoetis delivered an earnings surprise of 5.81%.
Shares of Zoetis have increased 4.5% in the year so far against the industry’s decrease of 8.4%.
Let's see how things are shaping up for this announcement.
Factors to Consider
Zoetis derives a majority of its revenues from a diversified product portfolio of medicines and vaccines used to treat and protect livestock and companion animals. The company reports business results under two geographical operating segments — the United States and International.
Solid sales from the dermatology portfolio strengthened the United States segment in the last-reported quarter, a trend that most likely continued in the first quarter as well. The company’s companion animal business has also been performing well, primarily owing to higher sales of the SimparicaTrio – the recently launched triple combination parasiticide for dogs.
In the last-reported quarter, sales of cattle products declined year over year – a trend that most likely continued in the first quarter as well. Sales of both swine and poultry products also declined in the last-reported quarter due to unfavorable market conditions related to the COVID-19 pandemic, a trend that most likely continued in the first quarter as well.
For the International segment, sales of companion animal products increased in the last-reported quarter. Sales also benefited as clinics expanded their operations following less COVID-19-related restrictions. The trend is expected to have continued in the first quarter as well. Growth in the company’s fish portfolio also went up due to increased market share for salmon vaccines and the acquisition of Fish Vet Group, a trend that most likely continued in the first quarter as well.
In February 2021, the European Commission granted marketing authorization to Solensia (frunevetmab) – a new feline osteoarthritis ("OA") treatment to alleviate pain. Solensia is the first injectable mAb licensed for the alleviation of pain associated with OA in cats. We expect more updates on the same at the upcoming earnings call.
Why a Likely Positive Surprise?
Our proven model predicts an earnings beat for Zoetis this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Zoetis has an Earnings ESP of +2.77% as the Zacks Consensus Estimate stands at $1.04 per share while the Most Accurate Estimate is pegged at $1.07 per share.
Zacks Rank: Zoetis has a Zacks Rank #3.
Zoetis Inc. Price and Consensus
Zoetis Inc. price-consensus-chart | Zoetis Inc. Quote
Other Stocks to Consider
Here are some other drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Axsome Therapeutics, Inc. (AXSM - Free Report) with an Earnings ESP of +23.83% and a Zacks Rank #3. The company is scheduled to report earnings on May 10.
Aerie Pharmaceuticals, Inc. with an Earnings ESP of +6.25% and a Zacks Rank #2. The company is scheduled to report earnings on May 5.
Milestone Pharmaceuticals Inc. (MIST - Free Report) has an Earnings ESP of +19.21% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>